Research advances in neuroblastoma immunotherapy

Latania Y. Booker, Titilope A. Ishola, Kanika Bowen-Jallow, Dai H. Chung

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of childhood cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.

Original languageEnglish (US)
Pages (from-to)112-117
Number of pages6
JournalCurrent Pediatric Reviews
Volume5
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Neuroblastoma
Immunotherapy
Research
Radioimmunotherapy
Neoplasms
Dendritic Cells
Therapeutics
Pediatrics
Cytokines
Antigens
Antibodies

Keywords

  • Antibody-mediated therapy
  • Cell-mediated therapy
  • Cytokine-mediated therapy
  • Immunotherapy
  • Neuroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Research advances in neuroblastoma immunotherapy. / Booker, Latania Y.; Ishola, Titilope A.; Bowen-Jallow, Kanika; Chung, Dai H.

In: Current Pediatric Reviews, Vol. 5, No. 2, 2009, p. 112-117.

Research output: Contribution to journalArticle

Booker, Latania Y. ; Ishola, Titilope A. ; Bowen-Jallow, Kanika ; Chung, Dai H. / Research advances in neuroblastoma immunotherapy. In: Current Pediatric Reviews. 2009 ; Vol. 5, No. 2. pp. 112-117.
@article{102ad4d51ff64f43bfdf489749f8a582,
title = "Research advances in neuroblastoma immunotherapy",
abstract = "Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15{\%} of childhood cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.",
keywords = "Antibody-mediated therapy, Cell-mediated therapy, Cytokine-mediated therapy, Immunotherapy, Neuroblastoma",
author = "Booker, {Latania Y.} and Ishola, {Titilope A.} and Kanika Bowen-Jallow and Chung, {Dai H.}",
year = "2009",
doi = "10.2174/157339609788185686",
language = "English (US)",
volume = "5",
pages = "112--117",
journal = "Current Pediatric Reviews",
issn = "1573-3963",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Research advances in neuroblastoma immunotherapy

AU - Booker, Latania Y.

AU - Ishola, Titilope A.

AU - Bowen-Jallow, Kanika

AU - Chung, Dai H.

PY - 2009

Y1 - 2009

N2 - Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of childhood cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.

AB - Neuroblastoma is the third most common pediatric cancer in the United States and is responsible for 15% of childhood cancer-related deaths. Despite major advances in multimodal therapy, the clinical outcome for several patients remains poor. Due to the desperate need for innovativation and improved success in the treatment and management of neuroblastoma, research interests in immunotherapy have been on the rise in recent years. Current immunotherapeutic approaches under investigation include antibodies targeting the neuroblastoma antigen GD2, cytokine stimulation of immune cells, use of immunocytokine conjugates, radioimmunotherapy, and tumor-primed dendritic cells. Immunotherapy could serve as a safe alternative or adjunct to current therapeutic protocols and would presumptively have fewer deleterious effects making it more favorable to patients.

KW - Antibody-mediated therapy

KW - Cell-mediated therapy

KW - Cytokine-mediated therapy

KW - Immunotherapy

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=68549136877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68549136877&partnerID=8YFLogxK

U2 - 10.2174/157339609788185686

DO - 10.2174/157339609788185686

M3 - Article

VL - 5

SP - 112

EP - 117

JO - Current Pediatric Reviews

JF - Current Pediatric Reviews

SN - 1573-3963

IS - 2

ER -